Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

BACKGROUND: The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been demonstrated in randomized, double-blind, placebo-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Driessen, Maurice T., Cohen, Joshua M., Patterson-Lomba, Oscar, Thompson, Stephen F., Seminerio, Michael, Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004075/
https://www.ncbi.nlm.nih.gov/pubmed/35410121
http://dx.doi.org/10.1186/s10194-022-01411-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004075/
https://www.ncbi.nlm.nih.gov/pubmed/35410121
http://dx.doi.org/10.1186/s10194-022-01411-1

Ejemplares similares